ID22933A - Fomulasi protien c terakivasi - Google Patents

Fomulasi protien c terakivasi

Info

Publication number
ID22933A
ID22933A IDW991133A ID991133A ID22933A ID 22933 A ID22933 A ID 22933A ID W991133 A IDW991133 A ID W991133A ID 991133 A ID991133 A ID 991133A ID 22933 A ID22933 A ID 22933A
Authority
ID
Indonesia
Prior art keywords
protient
fomulation
protient fomulation
Prior art date
Application number
IDW991133A
Other languages
English (en)
Indonesian (id)
Inventor
Andrew David Carlson
Theodore Arsay Sheliga
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ID22933A publication Critical patent/ID22933A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IDW991133A 1997-04-28 1998-04-24 Fomulasi protien c terakivasi ID22933A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28

Publications (1)

Publication Number Publication Date
ID22933A true ID22933A (id) 1999-12-16

Family

ID=21936854

Family Applications (2)

Application Number Title Priority Date Filing Date
IDW991254A ID23172A (id) 1997-04-28 1998-04-24 Metode yang diperbaiki untuk pengolahan protein c teraktivasi
IDW991133A ID22933A (id) 1997-04-28 1998-04-24 Fomulasi protien c terakivasi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IDW991254A ID23172A (id) 1997-04-28 1998-04-24 Metode yang diperbaiki untuk pengolahan protein c teraktivasi

Country Status (34)

Country Link
US (4) US6162629A (cs)
EP (2) EP0875563A3 (cs)
JP (2) JP4383546B2 (cs)
KR (2) KR100564189B1 (cs)
CN (2) CN1235638C (cs)
AR (2) AR012010A1 (cs)
AT (1) ATE285788T1 (cs)
AU (2) AU743531B2 (cs)
BR (2) BR9809292A (cs)
CA (2) CA2287267C (cs)
CO (2) CO4950523A1 (cs)
CZ (1) CZ298429B6 (cs)
DE (1) DE69828330T2 (cs)
DK (1) DK0875252T3 (cs)
EA (2) EA004881B1 (cs)
EG (1) EG23685A (cs)
ES (1) ES2234072T3 (cs)
HU (2) HUP0003401A3 (cs)
ID (2) ID23172A (cs)
IL (2) IL132325A (cs)
IN (2) IN183798B (cs)
MY (2) MY120984A (cs)
NO (2) NO995134L (cs)
NZ (2) NZ337828A (cs)
PE (2) PE84799A1 (cs)
PL (2) PL195642B1 (cs)
PT (1) PT875252E (cs)
SI (1) SI0875252T1 (cs)
SV (2) SV1998000050A (cs)
TR (2) TR199902529T2 (cs)
TW (2) TW585871B (cs)
UA (2) UA55448C2 (cs)
WO (2) WO1998048822A1 (cs)
ZA (2) ZA983497B (cs)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
NZ337828A (en) 1997-04-28 2001-06-29 Lilly Co Eli Activated protein C formulations having a bulking agent and a salt
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
IL142255A0 (en) * 1998-11-13 2002-03-10 Lilly Co Eli Method of treating heparin-induced thrombocytopenia
EP1131091B1 (en) * 1998-11-20 2003-04-02 Eli Lilly And Company Treatment of viral hemorrhagic fever with protein c
DE69905489T2 (de) * 1998-11-23 2003-09-11 Eli Lilly And Co., Indianapolis Protein c zur behandlung von sichelzellanämie und thalassämie
ATE264113T1 (de) * 1998-12-10 2004-04-15 Lilly Co Eli Verwendung von protein c zur behandlung von thrombozytopenischer purpura und hämolytisches urämisches syndrom
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
EP1289543A2 (en) * 2000-05-24 2003-03-12 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
ES2309167T3 (es) 2001-02-19 2008-12-16 Merck Patent Gmbh Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインｃの不活性化を抑制するための銅キレート剤の使用
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
EP1453529A4 (en) 2001-09-19 2007-09-26 Oklahoma Med Res Found TREATMENT OF SEPSIS WITH TAFI
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
AU2002365131B2 (en) 2001-10-15 2007-03-01 Novartis Vaccines And Diagnostics, Inc. Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)
JP2005530683A (ja) 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体組成物
JP2005528351A (ja) * 2002-03-08 2005-09-22 イーライ・リリー・アンド・カンパニー 活性化プロテインｃ製剤
KR20050013148A (ko) 2002-06-21 2005-02-02 노보 노르디스크 에이/에스 인자 ⅶ 폴리펩티드의 안정화된 고체 조성물
PL376219A1 (en) * 2002-10-29 2005-12-27 Alza Corporation Stabilized, solid-state polypeptide particles
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
EP1641487B1 (en) * 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
SG150552A1 (en) * 2004-03-17 2009-03-30 Chiron Corp Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
EP1773371A4 (en) * 2004-07-23 2009-12-30 Univ Rochester ACTIVATED PROTEIN C INHIBITS SIDE EFFECTS OF PLASMINOGEN ACTIVATOR IN THE BRAIN
CA2612859A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
PL2029740T3 (pl) * 2006-05-31 2012-11-30 Genzyme Corp Zastosowanie polisacharydów do promowania aktywności enzymatycznej
EP2041338A4 (en) * 2006-06-09 2009-09-30 Univ British Columbia INTERFERON GAMMA POLYMORPHISMS AS INDICATORS OF RESULT IN SERIOUSLY SICK SUBJECTS
ES2365832T3 (es) * 2007-03-05 2011-10-11 Cadila Healthcare Limited Composiciones que comprenden conjugados de peg-interferón alfa y rafinosa como crioprotector.
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
AU2008334099B2 (en) * 2007-11-30 2014-07-24 Abbvie Biotechnology Ltd. Protein formulations and methods of making same
CA2712057A1 (en) * 2008-01-15 2009-07-23 The University Of British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
CN104398471A (zh) * 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9357765B2 (en) 2012-04-03 2016-06-07 Smiths Medical Asd, Inc. Heparain-bulking agent compositions and methods thereof
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
IN2014DN11181A (cs) 2012-07-04 2015-10-02 Univ Sydney
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN106488773B (zh) 2014-04-16 2020-02-11 Zz生物技术有限责任公司 Apc类似物用于创伤愈合的用途
ES2890675T3 (es) 2014-04-16 2022-01-21 Zz Biotech Llc APC para uso en el tratamiento de cicatrices cutáneas anormales
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
MX388814B (es) * 2016-06-01 2025-03-20 Servier Ip Uk Ltd Formulaciones de oxido de polialquileno-asparaginasa y metodos de preparacion y uso del mismo.
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
WO1991012320A1 (en) * 1990-02-09 1991-08-22 Zymogenetics, Inc. Activated protein c with truncated light chain
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
NZ337828A (en) * 1997-04-28 2001-06-29 Lilly Co Eli Activated protein C formulations having a bulking agent and a salt
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
US6159468A (en) 2000-12-12
AU740753B2 (en) 2001-11-15
AR012010A1 (es) 2000-09-13
MY120984A (en) 2005-12-30
CZ298429B6 (cs) 2007-10-03
JP4383547B2 (ja) 2009-12-16
UA55448C2 (uk) 2003-04-15
IN183798B (cs) 2000-04-15
HUP0003401A3 (en) 2003-01-28
IL132325A (en) 2005-07-25
KR100564189B1 (ko) 2006-03-27
TR199902631T2 (xx) 2000-01-21
IN187157B (cs) 2002-02-16
ZA983497B (en) 1999-10-25
DK0875252T3 (da) 2005-04-25
US6436397B1 (en) 2002-08-20
KR20010020242A (ko) 2001-03-15
SI0875252T1 (en) 2005-06-30
JP2001524111A (ja) 2001-11-27
CZ381099A3 (cs) 2000-03-15
EP0875563A3 (en) 2000-08-02
WO1998048822A1 (en) 1998-11-05
PT875252E (pt) 2005-03-31
EP0875252B1 (en) 2004-12-29
PE86299A1 (es) 1999-09-17
EP0875252A2 (en) 1998-11-04
CA2288143A1 (en) 1998-11-05
CN1227025C (zh) 2005-11-16
KR100450856B1 (ko) 2004-10-02
CA2288143C (en) 2012-08-21
CN1254284A (zh) 2000-05-24
KR20010020325A (ko) 2001-03-15
EA002149B1 (ru) 2001-12-24
HUP0100284A3 (en) 2003-08-28
CO4940438A1 (es) 2000-07-24
HU224826B1 (en) 2006-02-28
CA2287267A1 (en) 1998-11-05
EG23685A (en) 2007-05-09
AU7161898A (en) 1998-11-24
AU740753C (en) 2002-10-10
BR9809304A (pt) 2000-10-17
AU743531B2 (en) 2002-01-31
US6395270B1 (en) 2002-05-28
MY118591A (en) 2004-12-31
AR015598A1 (es) 2001-05-16
NZ500346A (en) 2001-08-31
HK1016472A1 (en) 1999-11-05
HUP0003401A2 (hu) 2001-02-28
EA199900980A1 (ru) 2000-04-24
HUP0100284A2 (hu) 2001-06-28
NO995198L (no) 1999-10-25
IL132502A0 (en) 2001-03-19
PE84799A1 (es) 1999-09-16
ES2234072T3 (es) 2005-06-16
US6162629A (en) 2000-12-19
DE69828330T2 (de) 2005-10-13
CA2287267C (en) 2006-08-15
BR9809292A (pt) 2000-07-04
EP0875252A3 (en) 2000-07-26
TW585871B (en) 2004-05-01
NO995198D0 (no) 1999-10-25
PL195090B1 (pl) 2007-08-31
ATE285788T1 (de) 2005-01-15
PL336420A1 (en) 2000-06-19
IL132325A0 (en) 2001-03-19
TWI242443B (en) 2005-11-01
PL336889A1 (en) 2000-07-17
NZ337828A (en) 2001-06-29
ZA983496B (en) 1999-10-25
CO4950523A1 (es) 2000-09-01
SV1998000051A (es) 1998-12-11
JP2001527543A (ja) 2001-12-25
PL195642B1 (pl) 2007-10-31
AU7258998A (en) 1998-11-24
CN1235638C (zh) 2006-01-11
ID23172A (id) 2000-03-23
SV1998000050A (es) 1999-01-13
EP0875563A2 (en) 1998-11-04
EA004881B1 (ru) 2004-08-26
NO995134D0 (no) 1999-10-21
BR9809304B1 (pt) 2011-02-08
WO1998048818A1 (en) 1998-11-05
TR199902529T2 (xx) 2000-02-21
UA73071C2 (en) 2005-06-15
EA199900979A1 (ru) 2000-06-26
NO995134L (no) 1999-12-21
CN1261280A (zh) 2000-07-26
JP4383546B2 (ja) 2009-12-16
DE69828330D1 (de) 2005-02-03

Similar Documents

Publication Publication Date Title
ID22933A (id) Fomulasi protien c terakivasi
NO20003303D0 (no) Vaksine
DE69839603D1 (de) Zierenden proteins
ID23173A (id) Turunan pirol trisiklik atau pirazol
DE69808855D1 (de) Klebstoff
DE59802134D1 (de) Einknüpflager
DE69818756D1 (de) Aufwickelspulenverriegelungsmechanismus
ATA111897A (de) Kimme
DE69801399D1 (de) Urladen
DE69806878D1 (de) Etikettiereinrichtung
DE69820582D1 (de) Informationsverarbeitingssystem
ATA112597A (de) Snowboard - bindung
PT1015447E (pt) Derivado piperidinilmetiloxazolidinona
FI974129L (fi) Apuväline
KR980000298U (ko) 단추
BR9701194A (pt) Hidrociclo
ATA46498A (de) Kunststoffgleitbahn
LU90081B1 (fr) Serti plaque-clou
SE9700194D0 (sv) Hjälpmedel
NO970759D0 (no) Hjelpemiddel
FI3205U1 (fi) Teline
KR980000299U (ko) 단추
FI972731A0 (fi) Baerande grundelement
BR9700328A (pt) Conjunto tampa-recipiente
BR7702215U (pt) Conjunto pia-fogão